Alzheimer’s disease (AD) requires objective biomarkers to differentiate it from other dementias and guide timely care. SMSL offers CSF and blood biomarkers including Aβ1-42/Aβ1-40 ratio, total tau, p-Tau181/217, and neurofilament light (NfL), with optional APOE genotyping and panels for early-onset familial AD where indicated, plus rule-out labs (TSH, B12/folate, infection, autoimmune panels). Our ELISA, automated immunoassay, molecular and clinical chemistry solutions from the same broad partner network ensure analytical rigor for early detection, differential diagnosis, and longitudinal monitoring.